Your browser doesn't support javascript.
loading
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ß2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
Chen, Yiming; Neelapu, Sattva; Feng, Lei; Bi, Weiqi; Yang, Tian-Hui; Wang, Michael; Fanale, Michelle A; Westin, Jason R; Hagemeister, Fredrick B; Fayad, Luis E; Romaguera, Jorge E; Samaniego, Felipe; Turturro, Francesco; Fowler, Nathan H; McLaughlin, Peter; Cabanillas, Fernando; Oki, Yasuhiro; Nastoupil, Loretta J; Rodriguez, Alma.
Afiliação
  • Chen Y; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Neelapu S; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bi W; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang TH; Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang M; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fanale MA; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin JR; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fayad LE; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Romaguera JE; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Turturro F; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fowler NH; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McLaughlin P; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cabanillas F; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oki Y; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nastoupil LJ; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodriguez A; Departments of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. marodriguez@mdanderson.org.
Br J Haematol ; 175(2): 290-299, 2016 Oct.
Article em En | MEDLINE | ID: mdl-27448187
ABSTRACT
There are limited reports that baseline peripheral absolute neutrophil count (ANC), absolute monocyte count (AMC), absolute lymphocyte count (ALC) and serum ß2-microglobulin level independently predict survival in patients with diffuse large B-cell lymphoma (DLBCL). To confirm these findings, we analysed these parameters together with components of the International Prognostic Index (IPI) in patients with newly-diagnosed DLBCL. We evaluated baseline clinical features for their ability to predict survival in 817 newly diagnosed, previously untreated patients with DLBCL who received frontline treatments between October 2001 and December 2011. The median age at diagnosis was 58 years. Multivariate analysis identified elevated baseline ANC (P = 0·036), AMC (P = 0·028) and serum ß2-microglobulin level (P < 0·001), poor performance status (P < 0·001) and high number of extranodal disease sites (P = 0·0497) as independent unfavourable predictors of OS; serum ß2-microglobulin level was the strongest predictor of survival outcomes among all the parameters. High baseline serum ß2-microglobulin, ANC and AMC levels are independent prognostic factors for short overall survival in patients with newly diagnosed DLBCL. Our new model, based on the above five parameters, better stratifies patients into various risk categories than the IPI for newly diagnosed DLBCL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monócitos / Microglobulina beta-2 / Linfoma Difuso de Grandes Células B / Contagem de Leucócitos / Neutrófilos Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monócitos / Microglobulina beta-2 / Linfoma Difuso de Grandes Células B / Contagem de Leucócitos / Neutrófilos Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article